Termine Andrea, Fabrizio Carlo, Strafella Claudia, Caputo Valerio, Petrosini Laura, Caltagirone Carlo, Giardina Emiliano, Cascella Raffaella
IRCCS Santa Lucia Foundation, Genomic Medicine Laboratory UILDM, 00179 Rome, Italy.
IRCCS Santa Lucia Foundation, Laboratory of Experimental and Behavioral Neurophysiology, 00143 Rome, Italy.
J Pers Med. 2021 Apr 7;11(4):280. doi: 10.3390/jpm11040280.
In the big data era, artificial intelligence techniques have been applied to tackle traditional issues in the study of neurodegenerative diseases. Despite the progress made in understanding the complex (epi)genetics signatures underlying neurodegenerative disorders, performing early diagnosis and developing drug repurposing strategies remain serious challenges for such conditions. In this context, the integration of multi-omics, neuroimaging, and electronic health records data can be exploited using deep learning methods to provide the most accurate representation of patients possible. Deep learning allows researchers to find multi-modal biomarkers to develop more effective and personalized treatments, early diagnosis tools, as well as useful information for drug discovering and repurposing in neurodegenerative pathologies. In this review, we will describe how relevant studies have been able to demonstrate the potential of deep learning to enhance the knowledge of neurodegenerative disorders such as Alzheimer's and Parkinson's diseases through the integration of all sources of biomedical data.
在大数据时代,人工智能技术已被应用于解决神经退行性疾病研究中的传统问题。尽管在理解神经退行性疾病背后复杂的(表观)遗传学特征方面取得了进展,但对于这些疾病而言,进行早期诊断和制定药物再利用策略仍然是严峻的挑战。在这种背景下,可以利用深度学习方法整合多组学、神经影像学和电子健康记录数据,以尽可能准确地呈现患者情况。深度学习使研究人员能够找到多模态生物标志物,从而开发出更有效、个性化的治疗方法、早期诊断工具,以及用于神经退行性疾病药物发现和再利用的有用信息。在本综述中,我们将描述相关研究如何通过整合所有生物医学数据来源,证明深度学习在增强对阿尔茨海默病和帕金森病等神经退行性疾病的认识方面的潜力。